Sugi Predict

Sugi Predict / Compounds / SCHEMBL1887808

SCHEMBL1887808

SCHEMBL1887808

CC(C)(C)OC(=O)CCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)ON1C(=O)CCC1=O)C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.44
▸ POLB P06746 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ NOD1 Q9Y239 4/20 0.33
▸ EPHX2 P34913 1/20 0.32
▸ P2RY12 Q9H244 5/20 0.32
▸ HPGD P15428 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20450599 1.00 KMT2A (0.44) KMT2APOLBHDAC8L3MBTL1NOD1
SCHEMBL1889613 1.00 KMT2A (0.44) KMT2APOLBHDAC8L3MBTL1NOD1
SCHEMBL1677088 1.00 KMT2A (0.44) KMT2APOLBHDAC8L3MBTL1NOD1
SCHEMBL26413508 1.00 KMT2A (0.44) KMT2APOLBHDAC8L3MBTL1NOD1
SCHEMBL20450544 1.00 KMT2A (0.44) KMT2APOLBHDAC8L3MBTL1NOD1
SCHEMBL20467657 1.00 KMT2A (0.44) KMT2APOLBHDAC8L3MBTL1NOD1
SCHEMBL24819248 1.00 KMT2A (0.44) KMT2APOLBHDAC8L3MBTL1NOD1
SCHEMBL20144613 1.00 KMT2A (0.44) KMT2APOLBHDAC8L3MBTL1NOD1
SCHEMBL20467680 1.00 KMT2A (0.44) KMT2APOLBHDAC8L3MBTL1NOD1
SCHEMBL12666348 0.99 KMT2A (0.44) KMT2APOLBHDAC8L3MBTL1NOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4598938-A2 PEPTIDES FOR INCRETIN SYNTHESIS Eli Lilly and Company (US) 2025-08-13 — — EP disclosed
US-20250188019-A1 COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS ELI LILLY AND COMPANY 2025-06-12 — — US disclosed
WO-2024077149-A2 PEPTIDES FOR INCRETIN SYNTHESIS ELI LILLY AND COMPANY (US) 2024-04-11 — — WO disclosed
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK AS (DK) 2019-04-18 — — US disclosed
US-10259856-B2 Protease stabilized acylated insulin analogues NOVO NORDISK A/S (DK) 2019-04-16 — — US disclosed
US-9896496-B2 Derivative of an insulin analogue NOVO NORDISK A/S (DK) 2018-02-20 — — US disclosed
US-9896496-B2 Derivative of an insulin analogue NOVO NORDISK A/S (DK) 2018-02-20 — — US disclosed
EP-3055325-B1 NOVEL DERIVATIVE OF AN INSULIN ANALOGUE NOVO NORDISK AS (DK) 2018-01-03 — — EP disclosed
US-9688737-B2 Protease stabilized acylated insulin analogues NOVO NORDISK A/S (DK) 2017-06-27 — — US disclosed
EP-2910570-B1 Protease stabilized, acylated insulin analogues NOVO NORDISK AS (DK) 2016-10-12 — — EP disclosed
US-9045560-B2 Protease stabilized, acylated insulin analogues NOVO NORDISK A/S (DK) 2015-06-02 — — US disclosed
US-8791236-B2 Method of acylating a peptide or protein NOVO NORDISK A/S (DK) 2014-07-29 — — US disclosed
US-20140142280-A1 Method of Acylating a Peptide or Protein NOVO NORDISK A/S (DK) 2014-05-22 — — US disclosed
US-20140073564-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK A/S (DK) 2014-03-13 — — US disclosed
US-8637647-B2 Method of acylating a peptide or protein NOVO NORDISK A/S (DK) 2014-01-28 — — US disclosed
US-8637647-B2 Method of acylating a peptide or protein NOVO NORDISK A/S (DK) 2014-01-28 — — US disclosed
US-20110213131-A1 Method of Acylating a Peptide or Protein NOVO NORDISK A/S (DK) 2011-09-01 — — US disclosed
US-20110213131-A1 Method of Acylating a Peptide or Protein NOVO NORDISK A/S (DK) 2011-09-01 — — US disclosed
US-20110105720-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES NOVO NORDISK A/S (DK) 2011-05-05 — — US disclosed
US-20110098440-A1 Insulin Analogues with an Acyl and Alkylene Glycol Moiety NOVO NORDISK A/S (DK) 2011-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105720-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE KMT2A 2298/4885POLB 3022/4885HDAC8 609/4885
US-20250188019-A1 COMPOUNDS AND METHODS FOR LIQUID PHASE SYNTHESIS AQP1, CCNB1, CDK2 KMT2A 2041/4885POLB 272/4885HDAC8 3105/4885
US-20110098440-A1 Insulin Analogues with an Acyl and Alkylene Glycol Moiety IAPP, INSR, IGF1R KMT2A 418/4885POLB 3744/4885HDAC8 463/4885
US-20140073564-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE KMT2A 2298/4885POLB 3022/4885HDAC8 609/4885
US-20110213131-A1 Method of Acylating a Peptide or Protein DNPEP, PTMA, ANPEP KMT2A 2645/4885POLB 2484/4885HDAC8 2523/4885
US-20140142280-A1 Method of Acylating a Peptide or Protein DNPEP, PTMA, ANPEP KMT2A 2657/4885POLB 2401/4885HDAC8 2628/4885
US-20190112348-A1 PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES IAPP, IDE, LIPE KMT2A 2298/4885POLB 3022/4885HDAC8 609/4885
US-10259856-B2 Protease stabilized acylated insulin analogues IAPP, IDE, LIPE KMT2A 2426/4885POLB 3332/4885HDAC8 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.